Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (824)	4/20/1999 8:55:00 PM
From: jeffbas	Read Replies (1) \| Respond to of 1073

Re: NRGN - I found the following sentence from the 2/17 release appealing: ''This broad pipeline of research programs allows us to employ a strategy similar to that used by the major pharmaceutical companies of developing multiple drug candidates for a disease target, in order to increase our probability of success.'' My translation - A strategy similar to a large company should have a similar probability of success but dramatically greater impact on the share price of this small cap company - in other words a far better risk/reward. (Or are they probably giving much of the reward to companies like Pfizer.) Also, the fact that their burn rate relative to their cash seems quite good. Also, that a prior research program review indicated that NGD 91-3 seemed much more effective than the 91-2 product, which may not be effective. Now, what does an expert in the field think of this company at this price? Is there any catalyst to suggest that this won't be languishing here indefinitely, or dropping? (The stock has been in a declining channel for years.)